Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Stock Report

Market Cap: US$5.2b

Ionis Pharmaceuticals Management

Management criteria checks 2/4

Ionis Pharmaceuticals' CEO is Brett Monia, appointed in Jan 2020, has a tenure of 5.33 years. total yearly compensation is $15.40M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $5.97M. The average tenure of the management team and the board of directors is 5.3 years and 9 years respectively.

Key information

Brett Monia

Chief executive officer

US$15.4m

Total compensation

CEO salary percentage6.55%
CEO tenure5.3yrs
CEO ownership0.1%
Management average tenure5.3yrs
Board average tenure9yrs

Recent management updates

Recent updates

Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates

May 02
Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Apr 22

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way?

Apr 20
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt In A Risky Way?

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Mar 24
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
author-image

Anticipated Drug Launches Will Shift Biotech Company To Commercial Stage

Ionis is set to boost revenue through first-mover advantage with TRYNGOLZA and other product launches targeting unmet medical needs.

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Dec 23
Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 01
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

CEO Compensation Analysis

How has Brett Monia's remuneration changed compared to Ionis Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$458m

Dec 31 2024US$15mUS$1m

-US$454m

Sep 30 2024n/an/a

-US$359m

Jun 30 2024n/an/a

-US$366m

Mar 31 2024n/an/a

-US$385m

Dec 31 2023US$13mUS$961k

-US$366m

Sep 30 2023n/an/a

-US$409m

Jun 30 2023n/an/a

-US$309m

Mar 31 2023n/an/a

-US$329m

Dec 31 2022US$7mUS$825k

-US$270m

Sep 30 2022n/an/a

US$7m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$4m

Dec 31 2021US$13mUS$800k

-US$29m

Sep 30 2021n/an/a

-US$608m

Jun 30 2021n/an/a

-US$550m

Mar 31 2021n/an/a

-US$495m

Dec 31 2020US$11mUS$700k

-US$444m

Sep 30 2020n/an/a

US$94m

Jun 30 2020n/an/a

US$145m

Mar 31 2020n/an/a

US$169m

Dec 31 2019US$7mUS$528k

US$281m

Sep 30 2019n/an/a

US$433m

Jun 30 2019n/an/a

US$402m

Mar 31 2019n/an/a

US$366m

Dec 31 2018US$4mUS$508k

US$277m

Compensation vs Market: Brett's total compensation ($USD15.40M) is above average for companies of similar size in the US market ($USD8.76M).

Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.

CEO

Brett Monia (63 yo)

5.3yrs
Tenure
US$15,400,343
Compensation

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

Leadership Team

NamePositionTenureCompensationOwnership
Brett Monia
Founder5.3yrsUS$15.40m0.11%
$ 6.0m
Elizabeth Hougen
Executive VP of Finance & CFO12.3yrsUS$5.06m0.069%
$ 3.6m
Patrick O'Neil
Executive VP12.3yrsUS$3.43m0.036%
$ 1.9m
Richard Geary
Executive VP & Chief Development Officer16.8yrsUS$3.47m0.063%
$ 3.3m
Kyle Jenne
Executive VP & Chief Global Product Strategy Officer1.3yrsUS$4.30m0.0070%
$ 369.5k
Darren Gonzales
Chief Accounting Officer & Senior VP5.3yrsno datano data
C. Bennett
Executive VP & Chief Scientific Officer5.3yrsUS$958.87k0.059%
$ 3.1m
D. Walke
Senior Vice President of Investor Relationsno datano datano data
Tracy Berns
Senior VP and Chief Compliance & Quality Assurance Officerno datano datano data
Hayley Soffer
Vice President of Corporate Communications1.3yrsno datano data
Shannon L. Devers
Executive VP & Chief Human Resource Officer5.3yrsno data0.010%
$ 525.4k
Stanley Crooke
Scientific Advisor3.9yrsUS$2.28mno data
5.3yrs
Average Tenure
62.5yo
Average Age

Experienced Management: IONS's management team is seasoned and experienced (5.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brett Monia
Founder6.2yrsUS$15.40m0.11%
$ 6.0m
B. Parshall
Director24.7yrsUS$559.93k0.055%
$ 2.9m
Joan Herman
Independent Director5.9yrsUS$561.93k0.026%
$ 1.4m
Joseph Klein
Independent Director19.4yrsUS$563.93k0.010%
$ 542.2k
Joseph Wender
Lead Independent Director31.3yrsUS$619.93k0.083%
$ 4.4m
Michael Hayden
Independent Director6.7yrsUS$549.93k0.033%
$ 1.7m
Spencer Berthelsen
Independent Director23yrsUS$569.93k0.096%
$ 5.0m
Joseph Loscalzo
Independent Chairman of the Board11.3yrsUS$589.93k0.020%
$ 1.1m
Allene Diaz
Independent Director3.9yrsUS$551.93k0.0099%
$ 518.1k
Michael Yang
Independent Director1.4yrsUS$849.98k0.0012%
$ 63.5k
9.0yrs
Average Tenure
70yo
Average Age

Experienced Board: IONS's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/25 01:35
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 45 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
James BirchenoughBarclays
Huidong WangBarclays